Background. Adherence rates for recommended pre-transplant (pre-txp) vaccinations in pediatric solid-organ transplant (SOT) patients are variable and practice-dependent. Cleveland Clinic Children's Hospital (CCCH) pre-txp adherence rates for select vaccines have not been described. The purpose of this study was to evaluate pre-txp adherence rates for the following vaccines: hepatitis B, influenza, pneumococcal conjugate (PCV13), pneumococcal polysaccharide (PPSV23), and hepatitis A (if at-risk).
Methods. This retrospective cohort study included patients undergoing initial pediatric heart, kidney, liver, or intestine/multi-visceral transplant at CCCH between 1/1/14 and 7/31/17. Data collected from the electronic medical record and Ohio Department of Health Statewide Immunization Information System included demographics, transplant-related data, immunization administration history, and quantitative/qualitative values for titer/serology. The primary objective of vaccination adherence rate was defined as the aggregate of patients who had completed the vaccine series, had positive titer/serology data, or were ineligible to receive the vaccine due to age or administration restrictions. Data are descriptive in nature and reported as number (percent) or median (interquartile range), as appropriate.
Results. 64 pediatric SOT recipients met inclusion criteria. Median age was 7.9 (2.1, 15.8) years. Majority of patients were American (73%) and male (63%). Most common organ was heart (41%), followed by liver (25%), kidney (21%), and intestine/ multi-visceral (13%). Sixty-three (98%) patients underwent ID pre-txp evaluation. CCCH adherence rates were highest for hepatitis B at 92%, followed by PCV13 and PPSV23 at 84%, and influenza at 72%. Thirty-two (50%) patients were indicated to receive the hepatitis A vaccine and the respective adherence rate was 91%. Vaccination adherence by SOT team is described in Figure 1 .
Conclusion. CCCH pre-txp vaccination adherence rates are higher than previously reported. Opportunities for improvement include influenza vaccination adherence across all SOT teams and PCV13/PPSV23 vaccination adherence in intestine/ multi-visceral transplant patients. Background. Vaccine immune response is impaired in cancer patients. Follicular helper T lymphocytes (cTfh) are essential for high affinity and long lasting humoral response. The objective of this study was to evaluate the role of cTfh in the immune response induced by influenza vaccine in children with acute lymphoblastic leukemia (ALL).
Methods. Children with ALL in maintenance therapy and a control group of healthy children were included. Blood samples were taken on the day of vaccination (D0), and on day 28 (D28). The humoral response was evaluated by haemagglutination inhibition test and frequency of cTfh was studied by flow cytometry.
Results. Twenty-four children with ALL and 8 healthy children were included: 67 and 38% were women, median age of 5 years old in both groups. A 33% (8/24) of patients and 63% (5/8) of controls were seroprotected at D28. Seroprotected children at D28 were significantly older than non-protected ones (10 and 3.6 years respectively, P = 0,004). During follow-up, three children with ALL had influenza infection. An increase of percentage of cTfh cells from D0 to D28 was observed in both groups, but it was significant only in ALL patients (average for ALL, D0-D28: 18-23%, P = 0.003 and average for controls, D0-D28: 22-26%). No differences were found between seroprotected and non-seroprotected children in cTfh cell at D0 or D28. The increase of percentage of cTfh cells from D0 to D28 was observed in both groups, it was significant only in non-seroprotected subjects (average for seroprotected, D0-D28: 21-24% and average for non-seroprotected, D0-D28: 18-24%, P = 0.004).
Conclusion. Children with ALL achieved a lower seroprotection than healthy children. After vaccination, both groups had an increase of cTfh cells. We did not found an association between the percentage of cTfh cells and seroprotection at D28. The association between the lack of humoral response and cTfh dysfunction should be evaluated in further studies (We report public funding from Fondecyt grant Nº 11150970).
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